J Pediatr Infect Dis 2019; 14(05): 219-222
DOI: 10.1055/s-0039-1688930
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Serum Pentraxin 3 Concentration in Neonatal Sepsis

Fatih Battal
1  Department of Pediatrics, Çanakkale Onsekiz Mart University, Faculty of Medicine, Çanakkale, Turkey
,
Özgül Emel Bulut
2  Department of Neonatology, İstanbul Medeniyet University, Göztepe Education and Research Hospital, İstanbul, Turkey
,
Şule Yıldırım
1  Department of Pediatrics, Çanakkale Onsekiz Mart University, Faculty of Medicine, Çanakkale, Turkey
,
Hakan Aylanç
1  Department of Pediatrics, Çanakkale Onsekiz Mart University, Faculty of Medicine, Çanakkale, Turkey
,
Nazan Kaymaz
1  Department of Pediatrics, Çanakkale Onsekiz Mart University, Faculty of Medicine, Çanakkale, Turkey
,
Sema Uysal
3  Department of Biochemistry, Çanakkale Onsekiz Mart University, Faculty of Medicine, Çanakkale, Turkey
› Author Affiliations
Funding This work was supported by Scientific Research Projects Coordination Unit of Çanakkale Onsekiz Mart University. Project number 543.
Further Information

Publication History

07 December 2018

04 April 2019

Publication Date:
24 May 2019 (eFirst)

Abstract

Objective Neonatal sepsis is one of the most important causes of neonatal morbidity and mortality. Symptoms and signs of neonatal sepsis can be silent; therefore, laboratory investigation is necessary in cases of doubt or if there are risk factors. Early diagnosis is important for early intervention and treatment. The most valuable method for diagnosis is blood culture; however, false positivity due to contamination or false negativity despite ongoing fatal bacterial infections can be seen. Pentraxin 3 is a prototype of the long pentraxin family. It has some differences from C-reactive protein (CRP) in terms of gene organization and localization and production site. It is effective in the early phase of inflammation and it is detected as an early marker of sepsis in adults. The aim of this study was to investigate whether pentraxin 3 can be used as a marker in neonatal sepsis.

Materials and Methods Thirty newborns with suspected sepsis with antenatal history or the presence of clinical signs of sepsis, such as hypo/hyperthermia, feed intolerance, lethargy, hypotonia, irregular cardiac rhythms, bradycardia, cyanosis, apnea, respiratory distress, or metabolic acidosis, were enrolled in the study as a case group, and 28 healthy newborns were included as a control group. Serum pentraxin 3, procalcitonin, CRP, and hemogram in the study group and serum procalcitonin and pentraxin in the control group were examined.

Results Serum pentraxin 3 (pg/mL) and serum procalcitonin (ng/mL) levels were 2,273.82 ± 1,260.75 and 0.86 ± 0.52 in the case group and 957.41 ± 268.00 and 0.19 ± 0.18 in the control group (p < 0.001 for both), respectively.

Conclusion The present study showed that serum pentraxin 3 levels may be a useful marker in the diagnosis of neonatal sepsis.